Short Interest in InflaRx (NASDAQ:IFRX) Declines By 13.7%

InflaRx (NASDAQ:IFRXGet Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 415,200 shares, a drop of 13.7% from the January 15th total of 481,300 shares. Based on an average trading volume of 305,500 shares, the short-interest ratio is currently 1.4 days.

InflaRx Price Performance

Shares of IFRX opened at $2.00 on Tuesday. InflaRx has a 1 year low of $1.16 and a 1 year high of $2.82. The company’s 50 day simple moving average is $2.41 and its 200 day simple moving average is $1.92.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of InflaRx in a report on Thursday, January 16th.

Check Out Our Latest Report on IFRX

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC acquired a new stake in InflaRx in the fourth quarter valued at approximately $28,000. Walleye Capital LLC purchased a new position in InflaRx in the 4th quarter valued at about $51,000. Cubist Systematic Strategies LLC purchased a new position in InflaRx in the 4th quarter valued at about $55,000. Geode Capital Management LLC grew its stake in shares of InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after acquiring an additional 11,900 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in shares of InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after acquiring an additional 19,000 shares in the last quarter. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Company Profile

(Get Free Report)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

Featured Articles

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.